New diabetes drug to launch in June

05/2/2005 | Wall Street Journal, The

The U.S. FDA has approved Byetta, known generically as exenatide, to be used in combination with other oral drugs for those with Type 2 diabetes who are not yet dependent on insulin. The drug, a synthetic version of the saliva protein of a Gila monster, is injected twice a day and is designed to stimulate insulin production only when needed by the body. Eli Lilly and Amylin Pharmaceuticals are co-developers of the drug and will co-market it.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY